Late-life depression is a frequent and severe mental disorder. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
As persons age, their risk of developing late-life depression increases. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Use of omega-3 in psychiatric practice is on the rise. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Although it is clear that nutrition affects physical and metabolic functions in humans, the importance of nutrition in mental illness has often been overlooked. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Lithium is an established treatment for affective disorders with good evidence of antisuicidal properties. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recent studies have shown that lithium may block the accumulation of amyloid-beta (Abeta) peptides and to inhibit the hyperphosphorylation of tau via the inhibition of GSK-3alpha in the brain of mice. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
38/100
Depression has an overall prevalence of 5-8%. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
38/100
Depression and cognitive impairment are both common conditions in old age, and frequently occur together. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This brief report provides an introduction to the topic of cognitive functioning in late-life depression (LLD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We studied neuroinflammation in individuals with late-life depression, as a risk factor for dementia, using [11C]PK11195 positron emission tomography (PET). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This article focuses on diagnostic and nosologic challenges intrinsic to geriatric depression, including characteristics interfering with symptom and syndrome ascertainment, the impact of medical and cognitive disorders, the usefulness of screening instruments, and barriers imposed by treatment settings. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cognitive impairment in late-life depression is prevalent, disabling, and heterogeneous. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Major depressive disorder is a potentially debilitating condition that often is unrecognized or undertreated in the elderly. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Late life depression (LLD) frequently presents with cognitive impairment, and growing evidence suggests that these disease processes are "linked" in multiple ways. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Less than half of older adults with depression achieve remission with antidepressant medications, and rates of remission are even poorer for those with comorbid conditions. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The German psychiatrist Emil Kraepelin (1856 - 1926) is justly called father of modern psychiatry. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Elevated plasma amyloid beta 1-42 (Abeta42) level has been linked to increased risk for incident AD in cognitively-intact elderly. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
ACTH release results in the release of corticosteroids from the adrenal that, subsequently, through mineralocorticoid and glucocorticoid receptors, exert negative feedback on, among other things, the hippocampus, the pituitary and the hypothalamus. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Considerable evidence has accrued in the last two decades to support the hypothesis that alterations in serotonergic neuronal function in the central nervous system occur in patients with major depression. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The purpose of this article is to identify the cognitive deficits commonly associated with geriatric depression and describe their clinical significance. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
There is an increasing body evidence pointing to a close integration between the central nervous system (CNS) and immunological functions with lymphocytes playing therein a central role. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
These findings demonstrate that alpha-1 adrenoceptor stimulation in the PFC impairs cognitive function. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recent studies revealed a mechanism that ties together these disparate effects of lithium. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Increased levels of circulating AVP are also associated with the risk for suicide. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
A better understanding of the role of cytokines in various brain activities will enhance knowledge of specific psychobiological mechanisms in health and disease and provide opportunities for novel treatment interventions. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
From across this tag
9 of the 139 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- Telomere shortening in late-life depression: A potential marker of depression severity
- Linking late life depression and Alzheimer's disease: mechanisms and resilience
- Traumatic Brain Injury Increases Risk of Psychiatric Disorders Following Neurological Disease: Evidence from the UK Biobank Cohort
- Sex differences in the association between repetitive negative thinking and neurofilament light
- Association between depression, gender and Alzheimer's neuropathology in older adults without dementia
- Pharmacotherapy for Depression in Long-Term Care: A Real-World EHR Study
- Neuropsychiatric Ramifications of Severe COVID-19 and Other Severe Acute Respiratory Infections
- Neuromodulation and cognition in late-life depression
- Cerebrospinal fluid synaptic biomarker changes in bipolar disorder - A longitudinal case-control study
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →